Disease of thymus, other/unspecified

E4_THYMUSDISNAS

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E32.8, E32.9 Hospital discharge: ICD-9 — 254[8-9] Hospital discharge: ICD-8 — 25499 Cause of death: ICD-10 — E32.8, E32.9 Cause of death: ICD-9 — 254[8-9] Cause of death: ICD-8 — 25499 2 out of 7 registries used, show all original rules.	61
4. Check minimum number of events None	61
5. Include endpoints None	61
6. Filter based on genotype QC (FinnGen only)	59

Control definitions (FinnGen only)

Control exclude: E4_ENDOGLAND

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2

NAME	E4_THYMUSDISNAS
CONTROL_EXCLUDE	E4_ENDOGLAND
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E32[8-9]
HD_ICD_9	254[8-9]
HD_ICD_8	25499
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E32[8-9]
COD_ICD_9	254[8-9]
COD_ICD_8	25499
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Disease of thymus, other/unspecified based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	334	201	131
Only index persons	276	163	113
Unadjusted period prevalence (%)
Whole population	0.00	0.01	0.00
Only index persons	0.01	0.01	0.00
Median age at first event (years)
Whole population	54.02	57.68	48.43
Only index persons	49.25	52.02	45.26

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	59	38	21
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	48.37	48.16	48.74

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
61: Matched controls
610

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

E32.9

ICD-10 Finland

Disease of thymus, unspecified

+∞

51.5

F32.9

ICD-10 Finland

Depressive episode, unspecified

13.0

22.8

25499

ICD-8 Finland

Diseases of thymus gland

+∞

10.7

E32.8

ICD-10 Finland

Other diseases of thymus

+∞

8.5

T36

ICD-10 Finland

Poisoning by systemic antibiotics

10.3

6.4

D38.3

ICD-10 Finland

Neoplasm of uncertain or unknown behaviour: Mediastinum

+∞

6.3

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

Inpatient Hospital
21 [8717]

1.1e+00

1.5e+00

2.3e+00

1.0e+50

2.9e+00

1.7e+00

—

cases:60.38%

controls:33.27%

cases:37.74%

controls:11.60%

cases:16.98%

controls:2.09%

cases:33.96%

controls:0.00%

cases:15.09%

controls:0.95%

cases:39.62%

controls:11.05%

—

175

351

465

515

526

521

459

—

Psychiatry
26 [38004469]

1.8e+00

2.6e+00

—

2.1e+00

—

cases:20.75%

controls:3.99%

cases:16.98%

controls:1.52%

—

cases:11.32%

controls:1.55%

—

505

518

—

508

—

General Practice
1 [38004446]

8.6e-01

1.9e+00

—

1.0e+50

2.6e+00

1.9e+00

—

cases:22.64%

controls:11.03%

cases:20.75%

controls:3.61%

—

cases:24.53%

controls:0.00%

cases:11.32%

controls:0.95%

cases:26.42%

controls:5.04%

—

468

507

—

526

521

490

—

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

1.4e+00

2.8e+00

—

1.9e+00

—

cases:16.98%

controls:4.75%

cases:18.87%

controls:1.33%

—

cases:15.09%

controls:2.52%

—

501

519

—

503

—

Outpatient Visit
OP [9202]

1.1e+00

1.0e+00

1.5e+00

1.0e+50

2.0e+00

1.2e+00

—

cases:83.02%

controls:62.55%

cases:67.92%

controls:43.73%

cases:33.96%

controls:9.89%

cases:35.85%

controls:0.00%

cases:43.40%

controls:9.70%

cases:75.47%

controls:48.26%

—

329

197

230

296

474

526

475

249

267

—

Emergency Room Visit
ER [9203]

6.2e-01

1.3e+00

2.3e+00

1.0e+50

—

1.0e+00

—

cases:43.40%

controls:29.28%

cases:30.19%

controls:10.46%

cases:13.21%

controls:1.52%

cases:18.87%

controls:0.00%

—

cases:24.53%

controls:10.27%

—

154

372

471

518

526

—

463

—

Neurology
13 [38004458]

1.2e+00

1.1e+00

—

2.0e+00

—

cases:24.53%

controls:8.56%

cases:13.21%

controls:4.75%

—

cases:20.75%

controls:3.49%

—

481

501

—

498

—

ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]

-1.0e+50

—

2.6e+00

—

cases:0.00%

controls:1.14%

—

cases:11.32%

controls:0.97%

—

520

—

511

—

Internal Medicine
11 [38004456]

1.0e+00

1.4e+00

1.8e+00

1.0e+50

—

9.2e-01

—

cases:41.51%

controls:20.15%

cases:26.42%

controls:8.37%

cases:9.43%

controls:1.71%

cases:20.75%

controls:0.00%

—

cases:22.64%

controls:10.47%

—

106

420

482

517

526

—

462

—

Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]

1.5e+00

2.4e+00

—

cases:13.21%

controls:3.23%

cases:9.43%

controls:0.95%

—

509

521

—

Sleep apnoea
G47.3 [45562094]

2.2e+00

—

cases:13.21%

controls:1.71%

—

517

—

C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]

1.3e-01

7.9e-01

2.1e+00

—

1.0e+00

—

cases:16.98%

controls:15.21%

cases:20.75%

controls:10.65%

cases:15.09%

controls:2.09%

—

cases:26.42%

controls:11.63%

—

446

470

515

—

456

—

Rheumatology
66 [38004491]

2.0e+00

—

2.1e+00

—

cases:11.32%

controls:1.71%

—

cases:11.32%

controls:1.55%

—

517

—

508

—

Upper gastrointestinal surgery
106 [44777669]

1.3e+00

—

2.1e+00

—

cases:20.75%

controls:6.84%

—

cases:11.32%

controls:1.55%

—

490

—

508

—

Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]

-7.0e-02

3.3e-01

1.8e+00

—

1.4e+00

6.9e-01

—

cases:18.87%

controls:19.96%

cases:20.75%

controls:15.78%

cases:18.87%

controls:3.61%

—

cases:11.32%

controls:3.04%

cases:30.19%

controls:17.83%

—

105

421

443

507

—

510

424

—

Atrial fibrillation and flutter
I48 [45596206]

—

1.8e+00

—

cases:15.09%

controls:2.85%

—

511

—

esomeprazole; oral, parenteral
A02BC05 [21600100]

1.2e+00

1.7e+00

—

1.6e+00

—

cases:18.87%

controls:6.46%

cases:16.98%

controls:3.42%

—

cases:11.32%

controls:2.52%

—

492

508

—

503

—

Pulmonary Disease
29 [38004472]

1.7e+00

1.2e+00

—

1.9e+00

—

cases:24.53%

controls:5.70%

cases:11.32%

controls:3.61%

—

cases:11.32%

controls:1.94%

—

496

507

—

506

—

Outpatient Hospital
22 [8756]

9.0e-01

3.3e-01

—

1.0e+50

—

1.7e+00

—

cases:43.40%

controls:23.76%

cases:11.32%

controls:8.37%

—

cases:9.43%

controls:0.00%

—

cases:24.53%

controls:5.81%

—

125

401

482

—

526

—

486

—

Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

MCH [Entitic mass]
28539-5 [3035941]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

Leukocytes [#/volume] in Blood
26464-8 [3010813]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

Platelets [#/volume] in Blood
26515-7 [3007461]

-1.6e-01

4.1e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:17.68%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

433

506

—

510

104

412

—

Erythrocytes [#/volume] in Blood
26453-1 [3026361]

-1.6e-01

3.9e-01

1.6e+00

—

1.6e+00

5.4e-01

—

cases:18.87%

controls:21.48%

cases:24.53%

controls:18.06%

cases:16.98%

controls:3.80%

—

cases:13.21%

controls:3.04%

cases:30.19%

controls:20.16%

—

113

413

431

506

—

510

104

412

—

pantoprazole; oral, parenteral
A02BC02 [21600097]

8.7e-01

1.2e+00

—

1.4e+00

—

cases:26.42%

controls:13.12%

cases:18.87%

controls:6.65%

—

cases:22.64%

controls:6.59%

—

457

491

—

482

—

prednisolone
A07EA01 [21600653]

5.6e-01

1.4e+00

—

1.1e+00

—

cases:16.98%

controls:10.46%

cases:20.75%

controls:6.08%

—

cases:13.21%

controls:5.04%

—

471

494

—

490

—

prednisolone; oral, parenteral
H02AB06 [21602734]

5.6e-01

1.4e+00

—

1.1e+00

—

cases:16.98%

controls:10.46%

cases:20.75%

controls:6.08%

—

cases:13.21%

controls:5.04%

—

471

494

—

490

—

Infiltration anesthesia
WX110 [2001310767]

1.3e+00

9.0e-01

—

5.7e-01

—

cases:28.30%

controls:9.51%

cases:11.32%

controls:4.94%

—

cases:13.21%

controls:7.95%

—

476

500

—

475

—

paracetamol; oral, parenteral, rectal
N02BE01 [21604344]

8.1e-01

1.6e-01

—

1.3e+00

—

cases:37.74%

controls:21.29%

cases:15.09%

controls:13.12%

—

cases:35.85%

controls:13.18%

—

112

414

457

—

448

—

Pharmacy visit
OMOP4822462 [581458]

8.4e-03

9.0e-01

1.1e+00

—

8.9e-01

8.7e-01

—

cases:90.57%

controls:90.49%

cases:90.57%

controls:79.66%

cases:67.92%

controls:41.25%

—

cases:64.15%

controls:42.40%

cases:90.57%

controls:80.04%

—

476

419

107

217

309

—

223

303

413

103

—

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.90%

—

cases:0.00%

controls:1.16%

—

516

—

510

—

orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]

—

-1.0e+50

—

cases:0.00%

controls:2.71%

—

502

—

Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]

-1.0e+50

—

cases:0.00%

controls:1.14%

cases:0.00%

controls:1.14%

—

520

—

Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

combinations of corticosteroids
D07XB30 [21602188]

-3.0e-02

—

-1.0e+50

—

cases:9.43%

controls:9.70%

—

cases:0.00%

controls:2.91%

—

475

—

501

—

Urology
34 [38004474]

1.2e+00

—

-1.0e+50

—

cases:13.21%

controls:4.37%

—

cases:0.00%

controls:1.55%

—

503

—

508

—

valsartan; oral
C09CA03 [21601826]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Foot/toe symptom/complaint
L17 [2002000641]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

atorvastatin; oral
C10AA05 [21601860]

3.2e-01

—

cases:9.43%

controls:7.03%

—

489

—

losartan; oral
C09CA01 [21601824]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]

-1.0e+50

—

cases:0.00%

controls:3.23%

—

509

—

Stress incontinence
N39.3 [45539046]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

cefalexin; oral
J01DB01 [21602870]

7.0e-01

4.4e-01

—

3.9e-02

—

cases:39.62%

controls:24.52%

cases:13.21%

controls:8.94%

—

cases:9.43%

controls:9.11%

—

129

397

479

—

469

—

No disease
A97 [2002000230]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

ABO and Rh group [Type] in Blood
882-1 [3003694]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Respiratory and circulatory monitoring
WX700 [2001310817]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

hydrocortisone butyrate
D07AB02 [21602106]

4.4e-01

—

cases:9.43%

controls:6.27%

—

493

—

Disease of thymus, unspecified
E32.9 [45566742]

—

1.0e+50

—

1.0e+50

—

cases:79.25%

controls:0.00%

—

cases:9.43%

controls:0.00%

—

526

—

516

—

glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]

8.7e-01

—

cases:9.43%

controls:4.18%

—

504

—

Intramural leiomyoma of uterus
D25.1 [45547585]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]

—

-1.0e+50

—

cases:0.00%

controls:2.33%

—

504

—

lansoprazole; oral
A02BC03 [21600098]

6.2e-01

—

cases:9.43%

controls:5.32%

—

498

—

Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Nephrology
39 [38004479]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]

-2.6e-01

—

cases:13.21%

controls:16.54%

—

439

—

Vertigo/dizziness
N17 [2002000728]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

General health counselling
SPAT1312 [2001700413]

—

-1.0e+50

—

cases:0.00%

controls:1.94%

—

506

—

Carpal tunnel syndrome
G56.0 [45566891]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

piroxicam; oral, parenteral, rectal
M01AC01 [21603961]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Heart failure, unspecified
I50.9 [45576879]

—

-1.0e+50

—

cases:0.00%

controls:1.94%

—

506

—

hydroxocobalamin; parenteral
B03BA03 [21601123]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

hydroxyzine; oral, parenteral
N05BB01 [21604590]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Hypothyroidism, unspecified
E03.9 [45537945]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

azelastine; nasal
R01AC03 [21605035]

-1.0e+50

—

cases:0.00%

controls:3.04%

cases:0.00%

controls:1.52%

—

510

518

—

levofloxacin
S01AE05 [43534860]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Suture or treatment of traumatic wound
SPAT1149 [2001700250]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Small restoration
SFA00 [2001310357]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

Otolaryngology
4 [38004449]

1.9e-01

—

cases:11.32%

controls:9.51%

—

476

—

Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

rivaroxaban; oral
B01AF01 [43534761]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

cases:0.00%

controls:1.94%

—

518

—

506

—

potassium chloride; oral
A12BA01 [21600877]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

cases:0.00%

controls:0.97%

—

519

—

511

—

zopiclone; oral
N05CF01 [21604654]

6.1e-01

1.1e+00

—

-1.0e+50

—

cases:11.32%

controls:6.46%

cases:9.43%

controls:3.42%

—

cases:0.00%

controls:1.14%

—

492

508

—

520

—

More than one and less than three hours
ZXE10 [2001311401]

—

2.2e+00

—

cases:9.43%

controls:1.16%

—

510

—

influenza, inactivated, split virus or surface antigen
J07BB02 [21601335]

—

5.6e-01

-1.0e+50

—

cases:13.21%

controls:7.98%

cases:0.00%

controls:1.14%

—

484

520

—

Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]

-1.0e+50

—

cases:0.00%

controls:2.09%

—

515

—

furosemide and potassium-sparing agents
C03EB01 [21601554]

-1.0e+50

—

cases:0.00%

controls:1.52%

cases:0.00%

controls:1.14%

—

518

520

—

Supplier / Service Provider
OMOP5117446 [33004]

-7.3e-01

—

cases:13.21%

controls:23.95%

—

126

400

—

Diabetes non-insulin dependent
T90 [2002001131]

—

-1.0e+50

—

cases:0.00%

controls:3.88%

—

496

—

timolol
S01ED01 [21603699]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:3.04%

cases:0.00%

controls:2.85%

cases:0.00%

controls:1.14%

—

cases:0.00%

controls:1.14%

cases:0.00%

controls:2.52%

—

510

511

520

—

520

503

—

Body mass index
60621009 [4245997]

-8.3e-01

—

1.0e+50

—

cases:11.32%

controls:22.62%

—

cases:11.32%

controls:0.00%

—

119

407

—

516

—

Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Spirometry at the office
SPAT1059 [2001700160]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Spinal stenosis
M48.0 [45557888]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

Restricted health certificate
SPAT1283 [2001700384]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

510

—

Specific gravity of Urine by Refractometry
5810-7 [3019150]

1.9e+00

—

cases:9.43%

controls:1.52%

—

518

—

pH of Serum or Plasma
2753-2 [3018418]

—

-1.0e+50

—

cases:0.00%

controls:1.90%

—

516

—

CBC panel - Blood by Automated count
58410-2 [40761511]

-3.6e-02

9.3e-01

1.4e+00

—

1.4e+00

6.5e-01

—

cases:16.98%

controls:17.49%

cases:24.53%

controls:11.41%

cases:9.43%

controls:2.47%

—

cases:11.32%

controls:3.04%

cases:24.53%

controls:14.53%

—

434

466

513

—

510

441

—

salbutamol; inhalant
R03AC02 [21603256]

4.5e-01

3.9e-01

-1.0e+50

—

-1.0e+50

—

cases:18.87%

controls:12.93%

cases:11.32%

controls:7.98%

cases:0.00%

controls:1.33%

—

cases:0.00%

controls:1.33%

—

458

484

519

—

519

—

rabeprazole; oral
A02BC04 [21600099]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

516

—

Bacteria [Presence] in Urine
87829-8 [36304419]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.71%

—

cases:0.00%

controls:0.97%

—

517

—

511

—

Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]

—

-1.0e+50

—

cases:0.00%

controls:1.94%

—

506

—

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

2.4e-01

4.4e-01

1.7e+00

—

1.9e+00

7.4e-01

—

cases:13.21%

controls:10.65%

cases:15.09%

controls:10.27%

cases:9.43%

controls:1.90%

—

cases:9.43%

controls:1.52%

cases:22.64%

controls:12.21%

—

470

472

516

—

518

453

—

Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]

—

2.2e+00

—

cases:9.43%

controls:1.16%

—

510

—

paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]

—

-1.0e+50

—

cases:0.00%

controls:1.55%

—

508

—

Skin texture symptom/complaint
S21 [2002000986]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Colonoscopy Study observation
28023-0 [3022145]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

telithromycin; oral
J01FA15 [21602983]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

-4.2e-01

2.7e-01

1.3e+00

—

3.6e-01

—

cases:13.21%

controls:18.82%

cases:18.87%

controls:15.02%

cases:9.43%

controls:2.66%

—

cases:20.75%

controls:15.50%

—

427

447

512

—

436

—

alfuzosin; oral
G04CA01 [21602668]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Oncology Clinic/Center
261QX0200X [38004268]

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

Malignant neoplasm of prostate
C61 [45547509]

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Extraction of tooth
EBA00 [2001301923]

—

-1.0e+50

—

cases:0.00%

controls:1.74%

—

507

—

Type 2 diabetes mellitus, without complications
E11.9 [45561952]

1.1e+00

—

cases:9.43%

controls:3.23%

—

509

—

Urinary frequency/urgency
U02 [2002001138]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

terbinafine; oral
D01BA02 [21601967]

-1.0e+50

—

cases:0.00%

controls:2.66%

—

512

—

ketotifen
S01GX08 [21605092]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

cromoglicic acid
S01GX01 [21605085]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

cases:0.00%

controls:1.36%

—

520

—

509

—

Diabetes, insulin-treated
103 [2001600103]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

EKG study
11524-6 [3013512]

—

-1.0e+50

—

cases:0.00%

controls:2.52%

—

503

—

insulin aspart; parenteral
A10AB05 [21600719]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.47%

cases:0.00%

controls:2.66%

—

cases:0.00%

controls:0.95%

cases:0.00%

controls:2.91%

—

513

512

—

521

501

—

Simple examination of mouth
SAA01 [2001310274]

5.7e-01

4.1e-01

—

cases:20.75%

controls:12.93%

cases:9.43%

controls:6.46%

—

458

492

—

Depressive episode, unspecified
F32.9 [45571760]

—

1.0e+50

—

1.0e+50

—

cases:15.09%

controls:0.00%

—

cases:11.32%

controls:0.00%

—

526

—

526

—

Telehealth
OMOP5556618 [722455]

1.6e-01

7.3e-01

—

5.0e-01

—

cases:18.87%

controls:16.54%

cases:16.98%

controls:8.94%

—

cases:16.98%

controls:11.05%

—

439

479

—

459

—

25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]

—

-1.0e+50

—

cases:0.00%

controls:2.28%

—

514

—

prednisolone
S01BA04 [21603621]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

1.5e+00

—

cases:9.43%

controls:2.28%

—

514

—

dexamethasone; oral, parenteral
H02AB02 [21602730]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]

1.7e-01

6.4e-01

—

2.1e-01

—

cases:13.21%

controls:11.41%

cases:11.32%

controls:6.27%

—

cases:9.43%

controls:7.75%

—

466

493

—

476

—

Occupational health examination
Z10.0 [45581006]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

diclofenac; oral, parenteral, rectal
M01AB05 [21603945]

4.5e-01

—

cases:20.75%

controls:14.26%

—

451

—

Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]

-3.0e-02

5.6e-01

—

1.1e+00

—

cases:9.43%

controls:9.70%

cases:13.21%

controls:7.98%

—

cases:22.64%

controls:8.53%

—

475

484

—

472

—

Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Laboratory test
15220000 [4034850]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Hyperlipidaemia, unspecified
E78.5 [45537986]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

oxazepam; oral
N05BA04 [21604569]

1.2e+00

—

1.6e+00

—

cases:9.43%

controls:3.04%

—

cases:9.43%

controls:2.13%

—

510

—

505

—

Blood type and Crossmatch panel - Blood
34531-4 [3044640]

—

1.9e+00

—

cases:9.43%

controls:1.55%

—

508

—

Chronic kidney disease, unspecified
N18.9 [45553438]

-1.0e+50

—

cases:0.00%

controls:1.14%

cases:0.00%

controls:0.95%

—

520

521

—

Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

516

—

Knee X-ray examination without contrast
NG1AA [2001308049]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Sodium and Potassium panel [Moles/volume] - Serum or Plasma
34548-8 [3045783]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.85%

—

cases:0.00%

controls:2.13%

—

511

—

505

—

Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

trimethoprim; oral, parenteral
J01EA01 [21602931]

1.1e+00

—

cases:11.32%

controls:3.99%

—

505

—

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

—

1.2e+00

—

cases:13.21%

controls:4.46%

—

493

—

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

6.7e-02

4.5e-01

1.7e+00

—

1.6e+00

6.1e-01

—

cases:18.87%

controls:17.87%

cases:20.75%

controls:14.26%

cases:11.32%

controls:2.28%

—

cases:11.32%

controls:2.47%

cases:26.42%

controls:16.28%

—

432

451

514

—

513

432

—

ranitidine; oral, parenteral
A02BA02 [21600083]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Bacteria identified in Skin by Aerobe culture
620-5 [3007853]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

enoxaparin; parenteral
B01AB05 [21600976]

1.3e+00

—

cases:11.32%

controls:3.23%

—

509

—

INR in Blood by Coagulation assay
34714-6 [3032080]

—

9.7e-01

—

1.1e+00

—

cases:9.43%

controls:3.80%

—

cases:13.21%

controls:5.04%

—

506

—

490

—

Gynaecological examination (general)(routine)
Z01.4 [45542395]

1.7e+00

—

cases:9.43%

controls:1.90%

—

516

—

tizanidine; oral
M03BX02 [21604116]

3.5e-01

1.1e+00

—

cases:16.98%

controls:12.55%

cases:9.43%

controls:3.42%

—

460

508

—

frovatriptan; oral
N02CC07 [21604382]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

sulfasalazine; oral, rectal
A07EC01 [21600663]

-1.0e+50

—

cases:0.00%

controls:1.33%

cases:0.00%

controls:1.33%

—

519

—

Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]

6.7e-02

4.5e-01

1.6e+00

—

1.4e+00

6.4e-01

—

cases:18.87%

controls:17.87%

cases:20.75%

controls:14.26%

cases:11.32%

controls:2.47%

—

cases:9.43%

controls:2.47%

cases:26.42%

controls:15.89%

—

432

451

513

—

513

434

—

Sampling
SPAT1263 [2001700364]

—

-1.0e+50

—

cases:0.00%

controls:3.61%

—

507

—

Inpatient Visit
IP [9201]

7.8e-01

—

cases:11.32%

controls:5.51%

—

497

—

Person consulting for explanation of investigation findings
Z71.2 [45552100]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Monitoring of emergency patient
SPAT1104 [2001700205]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

acetylsalicylic acid; oral
B01AC06 [21600991]

—

-1.0e+50

—

cases:0.00%

controls:1.55%

—

508

—

Other and unspecified abdominal pain
R10.4 [45568113]

8.7e-01

—

2.2e+00

—

cases:9.43%

controls:4.18%

—

cases:9.43%

controls:1.16%

—

504

—

510

—

Two-surface restoration
SFA20 [2001310359]

6.4e-01

—

cases:16.98%

controls:9.70%

—

475

—

codeine and paracetamol
N02AJ06 [1123647]

1.7e-01

—

9.7e-01

—

cases:13.21%

controls:11.41%

—

cases:13.21%

controls:5.43%

—

466

—

488

—

Pediatric Medicine
37 [38004477]

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

Case Management Agency
251B00000X [38004193]

4.9e-01

6.1e-01

4.7e-01

—

6.6e-01

6.0e-01

—

cases:60.38%

controls:48.29%

cases:56.60%

controls:41.44%

cases:22.64%

controls:15.40%

—

cases:26.42%

controls:15.59%

cases:60.38%

controls:45.54%

—

254

272

218

308

445

—

444

235

281

—

Perimetry
XCK00 [2001301380]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Fall on same level from slipping, tripping and stumbling
W01 [45756243]

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]

—

2.2e+00

—

cases:9.43%

controls:1.16%

—

510

—

hypromellose
S01KA02 [21605115]

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

bisoprolol; oral
C07AB07 [21601689]

2.9e-01

5.5e-01

—

5.4e-01

—

cases:16.98%

controls:13.31%

cases:18.87%

controls:11.79%

—

cases:16.98%

controls:10.66%

—

456

464

—

461

—

Medical Oncology
90 [38004507]

—

1.4e+00

—

cases:9.43%

controls:2.52%

—

503

—

estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]

-1.2e-01

—

-1.0e+50

—

cases:13.21%

controls:14.64%

—

cases:0.00%

controls:2.09%

—

449

—

515

—

ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]

6.3e-01

3.7e-01

—

4.8e-01

—

cases:45.28%

controls:30.61%

cases:16.98%

controls:12.36%

—

cases:22.64%

controls:15.31%

—

161

365

461

—

437

—

ciclesonide; nasal
R01AD13 [43534836]

-1.0e+50

—

cases:0.00%

controls:2.47%

cases:0.00%

controls:1.14%

—

513

520

—

sildenafil; oral
G04BE03 [21602648]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.71%

—

cases:0.00%

controls:0.97%

—

517

—

511

—

fluticasone, combinations
R01AD58 [43534837]

-1.0e+50

—

cases:0.00%

controls:3.04%

cases:0.00%

controls:1.33%

—

510

519

—

clopidogrel; oral
B01AC04 [21600989]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

516

—

allopurinol; oral, parenteral
M04AA01 [21604131]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:2.91%

—

521

—

501

—

covid-19, RNA-based vaccine
J07BN01 [954934]

—

-1.0e+50

—

-1.0e+50

-3.0e-02

—

cases:0.00%

controls:1.33%

—

cases:0.00%

controls:1.14%

cases:9.43%

controls:9.69%

—

519

—

520

466

—

ciprofloxacin; oral, parenteral
J01MA02 [21603009]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

latanoprost
S01EE01 [21603710]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.71%

cases:0.00%

controls:1.33%

—

cases:0.00%

controls:1.74%

—

517

519

—

507

—

amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]

3.5e-01

-1.0e+50

—

cases:9.43%

controls:6.84%

cases:0.00%

controls:1.52%

—

490

518

—

Orthopedic Surgery
20 [38004465]

5.7e-01

—

-1.0e+50

—

cases:18.87%

controls:11.60%

—

cases:0.00%

controls:1.52%

—

465

—

518

—

clarithromycin; oral, parenteral
J01FA09 [21602977]

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

hydrocortisone
A07EA02 [21600654]

4.1e-01

—

cases:9.43%

controls:6.46%

—

492

—

Senile nuclear cataract
H25.1 [45581628]

—

-1.0e+50

—

cases:0.00%

controls:1.16%

—

510

—

Scheduled procedure
ZXD10 [2001311387]

8.2e-01

—

cases:9.43%

controls:4.37%

—

503

—

Assessment of need for aid
SPAT1229 [2001700330]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

ebastine; oral
R06AX22 [21603521]

-1.0e+50

—

cases:0.00%

controls:1.71%

cases:0.00%

controls:1.52%

—

517

518

—

warfarin; oral, parenteral
B01AA03 [21600965]

—

1.1e+00

-1.0e+50

—

9.6e-01

—

cases:11.32%

controls:4.18%

cases:0.00%

controls:1.33%

—

cases:11.32%

controls:4.65%

—

504

519

—

492

—

Ultrasound examination of lower leg veins
PH2AE [2001309451]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

pneumococcus, purified polysaccharides antigen conjugated
J07AL02 [21601313]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

mometasone; nasal
R01AD09 [21605051]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:3.23%

—

cases:0.00%

controls:0.95%

—

509

—

521

—

Need for immunization against other specified single viral diseases
Z25.8 [45547296]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

General symptom/complaint other
A29 [2002000163]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]

9.0e-01

1.5e+00

—

cases:26.42%

controls:12.74%

cases:11.32%

controls:2.85%

—

459

511

—

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

-5.2e-02

2.4e-01

1.3e+00

—

1.5e+00

4.3e-01

—

cases:15.09%

controls:15.78%

cases:16.98%

controls:13.88%

cases:9.43%

controls:2.66%

—

cases:9.43%

controls:2.28%

cases:20.75%

controls:14.53%

—

443

453

512

—

514

441

—

Functional capacity evaluation
443351003 [40481051]

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

pramipexole; oral
N04BC05 [21604477]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

finasteride; oral
D11AX10 [21602350]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.66%

cases:0.00%

controls:1.52%

—

cases:0.00%

controls:1.74%

—

512

518

—

507

—

hydrocortisone buteprate
D07AB11 [21602115]

4.4e-01

—

cases:9.43%

controls:6.27%

—

493

—

IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Chest pain, unspecified
R07.4 [45558450]

—

1.9e+00

—

cases:9.43%

controls:1.52%

—

518

—

Preventive oral health care, short
SCA01 [2001310302]

—

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Contraception intrauterine
W12 [2002001212]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]

—

1.0e+00

—

1.4e+00

—

cases:9.43%

controls:3.61%

—

cases:9.43%

controls:2.52%

—

507

—

503

—

Glaucoma suspect
H40.0 [45567051]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Occupational therapy
R4120 [2001310234]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

pseudoephedrine, combinations; oral
R01BA52 [21603213]

4.7e-01

—

cases:9.43%

controls:6.08%

—

494

—

Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

norethisterone and ethinylestradiol
G03AA05 [21602478]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Preventive immunization/medic
-44 [2002000115]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

metoprolol; oral, parenteral
C07AB02 [21601684]

—

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

piroxicam; ointment
M02AA07 [21604043]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Albumin [Mass/volume] in Urine
1754-1 [3012516]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:3.99%

—

cases:0.00%

controls:3.29%

—

505

—

499

—

Counselling and guidance which enhance independent living
R2130 [2001310196]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

pH of Venous blood
2746-6 [3012544]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

naproxcinod
M01AE18 [40254094]

-3.0e-02

—

-1.0e+50

—

cases:9.43%

controls:9.70%

—

cases:0.00%

controls:3.10%

—

475

—

500

—

levothyroxine sodium; oral, parenteral
H03AA01 [21602754]

3.3e-01

3.1e-01

—

4.6e-01

—

cases:11.32%

controls:8.37%

cases:11.32%

controls:8.56%

—

cases:13.21%

controls:8.72%

—

482

481

—

471

—

Acute bronchitis, unspecified
J20.9 [45562445]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

quetiapine; oral
N05AH04 [21604544]

1.6e+00

—

cases:9.43%

controls:2.09%

—

515

—

azithromycin; oral, parenteral
J01FA10 [21602978]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

3.6e-02

6.9e-01

—

1.6e-01

—

cases:15.09%

controls:14.64%

cases:15.09%

controls:8.17%

—

cases:13.21%

controls:11.43%

—

449

483

—

457

—

Laboratory Visit
OMOP4822461 [32036]

-1.4e-01

2.1e-01

1.3e+00

—

9.1e-01

5.5e-01

—

cases:20.75%

controls:23.19%

cases:24.53%

controls:20.91%

cases:22.64%

controls:7.41%

—

cases:15.09%

controls:6.65%

cases:35.85%

controls:24.42%

—

122

404

110

416

487

—

491

126

390

—

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

—

1.4e+00

—

1.4e+00

—

cases:11.32%

controls:3.04%

—

cases:11.32%

controls:3.10%

—

510

—

500

—

orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]

—

-1.0e+50

—

cases:0.00%

controls:2.71%

—

502

—

Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]

-1.9e-01

2.0e-01

—

-1.0e+50

—

cases:13.21%

controls:15.59%

cases:13.21%

controls:11.03%

—

cases:0.00%

controls:1.14%

—

444

468

—

520

—

Leg/thigh symptom/complaint
L14 [2002000638]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

rosuvastatin; oral
C10AA07 [21601862]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:3.80%

—

cases:0.00%

controls:1.14%

—

506

—

520

—

Endocrinology
46 [38004485]

—

-1.0e+50

—

cases:0.00%

controls:3.04%

—

510

—

antibiotics in combination with other drugs
S01AA20 [21603571]

8.8e-01

—

cases:15.09%

controls:6.84%

—

490

—

One-surface restoration
SFA10 [2001310358]

2.2e-01

—

3.9e-01

—

cases:11.32%

controls:9.32%

—

cases:9.43%

controls:6.59%

—

477

—

482

—

digoxin; oral, parenteral
C01AA05 [21600234]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

miconazole
D01AC02 [21601921]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

glibenclamide; oral
A10BB01 [21600750]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]

6.4e-01

—

cases:15.09%

controls:8.56%

—

481

—

Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Low back symptom/complaint
L03 [2002000628]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

telmisartan and diuretics
C09DA07 [21601839]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

General psychiatric examination, not elsewhere classified
Z00.4 [45605094]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

valsartan and amlodipine
C09DB01 [21601842]

-1.0e+50

—

cases:0.00%

controls:1.14%

cases:0.00%

controls:0.95%

—

520

521

—

SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]

—

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Emergency Medicine
93 [38004510]

4.1e-01

—

1.0e+50

—

1.3e+00

—

cases:9.43%

controls:6.46%

—

cases:9.43%

controls:0.00%

—

cases:15.09%

controls:4.65%

—

492

—

526

—

492

—

Other diseases of thymus
E32.8 [45537969]

—

1.0e+50

—

cases:15.09%

controls:0.00%

—

526

—

Memory test
SPAT1053 [2001700154]

—

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

Cerebral infarction, unspecified
I63.9 [45596216]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

fusidic acid
D09AA02 [21602265]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.09%

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:0.97%

—

515

521

—

511

—

loratadine; oral
R06AX13 [21603514]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

chloramphenicol
S01AA01 [21603554]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

Recording of ECG
SPAT1097 [2001700198]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

—

-1.0e+50

—

1.5e+00

—

cases:0.00%

controls:3.61%

—

cases:13.21%

controls:3.29%

—

507

—

499

—

Parabulbar anesthesia
WX140 [2001310772]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Teeth/gum symptom/complaint
D19 [2002000318]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.47%

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:2.13%

—

513

521

—

505

—

pivmecillinam; oral
J01CA08 [21602827]

9.4e-01

—

cases:16.98%

controls:7.41%

—

487

—

Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]

-2.5e-01

7.6e-02

—

-1.0e+50

—

cases:13.21%

controls:16.35%

cases:13.21%

controls:12.36%

—

cases:0.00%

controls:1.14%

—

440

461

—

520

—

Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:0.97%

—

521

—

511

—

platelet aggregation inhibitors excl. heparin - combinations
B01AC30 [21601005]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]

3.7e-01

8.6e-01

1.7e+00

—

1.6e+00

8.9e-01

—

cases:16.98%

controls:12.36%

cases:22.64%

controls:11.03%

cases:13.21%

controls:2.66%

—

cases:11.32%

controls:2.47%

cases:24.53%

controls:11.82%

—

461

468

512

—

513

455

—

Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]

—

-1.0e+50

—

cases:0.00%

controls:1.94%

—

506

—

tadalafil; oral
G04BE08 [21602653]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Screening procedure
SPAT1324 [2001700425]

—

-1.0e+50

—

cases:0.00%

controls:2.66%

—

512

—

Anaemia, unspecified
D64.9 [45600610]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Ankle symptom/complaint
L16 [2002000640]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

insulin glargine; parenteral
A10AE04 [21600739]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:3.42%

cases:0.00%

controls:3.99%

—

cases:0.00%

controls:1.14%

cases:0.00%

controls:4.26%

—

508

505

—

520

494

—

Ileoscopy through colon
UJF30 [2001305028]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.90%

cases:0.00%

controls:1.33%

—

cases:0.00%

controls:2.13%

—

516

519

—

505

—

Other angina pectoris stenosed coronary artery
I20.81 [2000502397]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

finasteride; oral
G04CB01 [21602675]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.66%

cases:0.00%

controls:1.52%

—

cases:0.00%

controls:1.74%

—

512

518

—

507

—

mesalazine; oral, rectal
A07EC02 [21600664]

-1.0e+50

—

cases:0.00%

controls:1.52%

cases:0.00%

controls:1.33%

—

518

519

—

temazepam; oral
N05CD07 [21604642]

1.0e+00

—

cases:9.43%

controls:3.61%

—

507

—

Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

glucagon; nasal, parenteral
H04AA01 [21602778]

-1.0e+50

—

cases:0.00%

controls:2.09%

—

515

—

letrozole; oral
L02BG04 [21603842]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

clindamycin; vaginal
G01AA10 [21602372]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

516

—

Cardiology
6 [38004451]

5.2e-01

1.6e+00

—

-1.0e+50

—

cases:11.32%

controls:7.03%

cases:11.32%

controls:2.47%

—

cases:0.00%

controls:0.95%

—

489

513

—

521

—

orphenadrine, combinations
M03BC51 [21604113]

—

-1.0e+50

—

cases:0.00%

controls:0.97%

—

511

—

Memory disturbance
P20 [2002000816]

-1.0e+50

—

cases:0.00%

controls:1.71%

—

517

—

doxycycline; oral, parenteral
J01AA02 [21602800]

9.0e-02

7.0e-01

—

cases:22.64%

controls:21.10%

cases:13.21%

controls:7.03%

—

111

415

489

—

Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Office Visit
OMOP4822458 [581477]

7.7e-01

1.3e+00

—

1.8e+00

—

cases:18.87%

controls:9.70%

cases:11.32%

controls:3.23%

—

cases:11.32%

controls:2.13%

—

475

509

—

505

—

Other and unspecified skin changes
R23.8 [45573020]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Gout
M10 [45533711]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

chondroitin sulfate
M01AX25 [21604013]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Coloscopy
UJF32 [2001305029]

1.1e+00

—

cases:9.43%

controls:3.42%

—

508

—

Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]

—

-1.0e+50

—

cases:0.00%

controls:1.36%

—

509

—

Intravenous
ZX120 [2001311495]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

Basic examination of mouth
SAA02 [2001310275]

6.4e-01

—

cases:16.98%

controls:9.70%

—

475

—

Photography of fundus of eye
XCK10 [2001301381]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.47%

cases:0.00%

controls:1.71%

—

cases:0.00%

controls:0.97%

—

513

517

—

511

—

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

3.7e-01

2.6e-01

—

cases:13.21%

controls:9.51%

cases:9.43%

controls:7.41%

—

476

487

—

Body height measure
50373000 [4177340]

-8.3e-01

—

1.0e+50

—

cases:11.32%

controls:22.62%

—

cases:11.32%

controls:0.00%

—

119

407

—

516

—

estriol; oral, parenteral, vaginal
G03CA04 [21602518]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

521

—

Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]

-1.0e+50

—

cases:0.00%

controls:1.52%

—

518

—

Dry eye syndrome
H04.10 [2000502254]

-1.0e+50

—

cases:0.00%

controls:1.33%

—

519

—

Audiometric test
21727005 [4071702]

-1.0e+50

—

cases:0.00%

controls:2.09%

—

515

—

furosemide; oral, parenteral
C03CA01 [21601518]

6.5e-01

9.8e-01

—

1.1e+00

—

cases:9.43%

controls:5.13%

cases:11.32%

controls:4.56%

—

cases:11.32%

controls:4.26%

—

499

502

—

494

—

Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]

-1.0e+50

—

cases:0.00%

controls:1.14%

—

520

—

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3021601) Nitrite [Presence] in Urine by Test strip

264

3.39

4.53

4.5

3.8

0.00

estimate

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

5.48

4.34

1.3

—

(3035350) Ketones [Presence] in Urine by Test strip

269

3.28

4.29

4.5

3.8

0.00

28.49

estimate

—

(3041096) Erythrocytes [Presence] in Urine by Automated

149

2.99

4.23

3.8

3.1

0.00

estimate

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

198

3.00

4.21

4.2

3.5

0.00

0.05

estimate

—

(3009261) Glucose [Presence] in Urine by Test strip

271

3.24

4.20

4.5

3.8

0.00

estimate

—

(3015235) Bicarbonate [Moles/volume] in Capillary blood

6.42

4.18

2.2

1.8

25.32

23.95

mmol/l

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

4.57

3.99

1.4

—

(3023520) Reticulocytes [#/volume] in Blood

3.74

3.94

1.6

4.6

56.84

83.23

e9/l

—

(3023368) Bacteria identified in Blood by Culture

136

2.77

3.59

5.4

3.8

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

194

2.70

3.53

5.7

4.2

73.74

38.56

ng/l

0.32

128

(3015736) pH of Urine

214

2.66

3.41

4.3

3.5

6.25

6.14

0.28

114

(3027945) Reticulocytes/Erythrocytes in Blood

3.05

3.06

2.2

4.5

1.63

1.99

1.23

(3024561) Albumin [Mass/volume] in Serum or Plasma

217

2.44

2.88

6.6

5.4

33.54

36.05

g/l

1.43

207

(3019060) Gas panel - Arterial blood

3.65

2.66

4.0

4.6

—

(3043409) Potassium [Moles/volume] in Arterial blood

4.99

2.33

6.0

2.7

3.78

4.03

mmol/l

—

(40767503) Oxygen content in Capillary blood by calculation

5.93

2.25

1.4

2.7

17.54

14.70

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

217

2.13

2.18

2.5

2.3

100.88

95.83

pmol/l

0.30

113

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

239

2.09

2.06

4.4

2.9

—

estimate

—

(3006504) Eosinophils/Leukocytes in Blood

241

2.06

1.99

7.3

6.9

2.58

2.78

0.21

222

(3026008) Bacteria identified in Urine by Culture

161

2.07

1.96

4.6

3.2

—

(3022096) Basophils/Leukocytes in Blood

242

2.05

1.96

7.4

6.9

0.78

0.69

0.38

222

(3019069) Monocytes/Leukocytes in Blood

243

2.03

1.92

7.5

7.0

8.50

8.61

0.07

226

(3021901) Oxygen saturation in Capillary blood

4.43

1.86

1.2

1.8

89.34

89.96

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

131

2.06

1.82

3.6

2.4

—

(3002030) Lymphocytes/Leukocytes in Blood

247

1.98

1.80

7.6

6.8

25.30

27.85

0.60

232

(1616796) Gas panel - Central venous blood

4.09

1.75

1.6

—

(3018010) Neutrophils/Leukocytes in Blood

242

1.91

1.66

7.5

6.7

59.31

57.92

0.26

226

(3029937) Albumin [Presence] in Urine by Test strip

152

1.95

1.66

4.9

3.7

0.00

estimate

—

(3025941) Bacteria identified in Stool by Culture

2.90

1.63

1.6

1.2

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.07

1.59

1.6

2.0

—

(3028626) Oxygen [Partial pressure] in Capillary blood

3.53

1.55

1.2

1.6

8.84

8.02

kpa

—

(3020891) Body temperature

3.05

1.54

6.5

3.2

36.92

36.91

°c

—

(42870588) Differential panel, method unspecified - Blood

174

1.86

1.50

5.6

6.3

—

(3018418) pH of Serum or Plasma

148

1.89

1.49

3.5

4.4

7.41

7.40

0.34

106

(3022313) Gas panel - Capillary blood

2.59

1.44

5.3

4.4

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

2.09

1.29

3.0

2.0

—

(3044640) Blood type and Crossmatch panel - Blood

174

1.74

1.23

4.3

2.3

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

2.45

1.22

1.7

1.2

—

(3021960) Folate [Moles/volume] in Serum or Plasma

149

1.75

1.18

2.2

1.8

17.72

22.70

nmol/l

0.58

128

(3042936) Bacteria identified in Isolate by Culture

1.93

1.13

2.2

1.9

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

294

1.66

1.07

12.4

11.7

3.99

3.91

e9/l

0.08

257

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

2.19

1.07

18.3

12.8

0.51

0.66

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

2.19

1.07

18.3

12.9

1.06

1.19

—

(3018095) Leukocytes [#/volume] in Urine

190

1.64

1.04

4.8

4.3

53.62

30.91

e6/l

0.59

123

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

154

1.67

1.03

4.1

2.7

55.68

56.76

u/l

0.04

145

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.89

1.01

1.8

1.7

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

176

1.60

0.93

4.0

3.2

—

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

1.99

0.92

1.3

—

(3022145) Colonoscopy Study observation

1.94

0.90

1.0

1.3

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.90

0.90

3.2

2.0

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.84

0.89

1.6

1.7

—

(3014111) Lactate [Moles/volume] in Serum or Plasma

1.89

0.88

12.6

10.5

1.17

0.99

mmol/l

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

2.03

0.87

7.8

10.2

25.67

24.18

mmol/l

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.78

0.81

1.3

1.6

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

1.78

0.81

16.5

8.7

102.64

104.30

mmol/l

0.33

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

1.91

0.81

16.0

12.8

24.22

24.35

mmol/l

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

0.81

0.0

1.0

—

0.53

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

0.81

0.0

1.1

—

1.54

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.00

0.81

0.0

1.1

—

0.83

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.78

0.79

1.8

1.5

—

(3021589) Normoblasts [#/volume] in Blood

210

1.51

0.79

14.0

12.1

0.01

0.00

e9/l

0.48

163

(3004588) Protein electrophoresis panel - Serum or Plasma

1.95

0.77

2.3

2.6

—

(40768804) Tissue Pathology biopsy report

218

0.64

0.75

1.6

2.0

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

2.09

0.74

5.2

5.0

23.64

24.63

mmol/l

—

(3036481) Cortisol [Moles/volume] in Serum or Plasma

1.73

0.70

1.2

1.7

373.90

398.91

nmol/l

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.71

0.69

1.1

1.8

—

(3000991) Gas panel - Venous blood

1.71

0.69

15.0

11.4

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

273

1.45

0.68

9.5

6.6

13.76

10.42

umol/l

0.57

263

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

105

1.57

0.68

3.3

4.8

1.06

1.71

ug/l

1.69

100

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

1.72

0.63

1.0

2.8

2.30

1.53

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

347

1.44

0.62

3.2

3.1

—

(3000492) Spirometry study

1.59

0.61

1.1

1.3

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.59

0.61

4.0

3.2

—

(3012516) Albumin [Mass/volume] in Urine

163

1.44

0.59

2.6

3.5

38.61

58.87

mg/l

0.23

107

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.52

0.49

3.4

3.2

9.82

4.01

e6/l

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.49

0.49

2.2

1.6

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

461

1.47

0.47

7.2

6.0

38.36

38.89

mmol/mol

0.20

436

(3000850) Epithelial cells [#/volume] in Urine

114

1.42

0.46

3.4

2.8

8.85

4.79

e6/l

0.54

103

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.45

0.44

1.3

—

(3020682) Albumin/Creatinine [Ratio] in Urine

162

1.35

0.43

3.7

4.2

3.09

8.53

mg/mmol

0.94

105

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.56

0.42

1.4

2.1

3.10

6.17

ug/l

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

499

1.47

0.42

27.8

15.9

32.36

20.32

mg/l

1.45

400

(4034850) Laboratory test

0.00

0.42

0.0

11.5

—

(3000494) Fungus identified in Specimen by Culture

1.40

0.40

1.4

1.5

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.40

0.0

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

100

1.38

0.37

2.5

1.9

—

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

523

1.52

0.36

17.5

12.0

22.95

25.85

u/l

1.14

512

(3003694) ABO and Rh group [Type] in Blood

140

1.30

0.32

2.1

1.4

—

(40768797) Stomach Pathology biopsy report

1.38

0.30

1.3

1.2

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.36

0.30

2.0

1.7

—

(40761511) CBC panel - Blood by Automated count

517

1.39

0.24

26.3

13.1

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

117

1.26

0.23

1.4

1.3

2.13

2.23

u/ml

—

(40761536) Microorganisms panel - Urine sediment

1.24

0.22

7.6

3.8

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

0.00

0.21

0.0

3.2

—

32.70

—

(3042631) Mycobacterium sp identified in Specimen

0.00

0.21

0.0

4.4

—

(3042111) Morphology [Interpretation] in Bone marrow Narrative

0.00

0.21

0.0

1.7

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

0.21

0.0

4.2

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.5

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

0.00

0.21

0.0

1.1

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

0.00

0.21

0.0

1.4

—

(4094501) Cardiovascular stress test using bicycle ergometer

0.00

0.21

0.0

1.0

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.21

0.0

2.2

—

0.00

—

(4035726) Immunohistochemistry procedure

1.22

0.20

1.2

1.4

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

1.20

0.20

4.0

2.4

19.50

32.60

u/l

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.17

0.20

6.0

6.4

—

(3002256) Pathology report gross observation

0.75

0.18

1.2

1.3

—

(1761868) Lipid panel - Serum or Plasma

201

0.85

0.16

3.0

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

1.21

0.13

3.8

3.1

0.36

0.94

e6/l

—

(40760892) CBC W Ordered Manual Differential panel - Blood

116

1.15

0.10

11.6

6.0

—

(3005322) IgE [Units/volume] in Serum or Plasma

1.12

0.10

1.0

1.2

13.96

513.51

u/ml

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

481

0.90

0.06

4.0

4.2

1.34

1.28

mmol/l

0.21

441

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

201

1.07

0.03

1.6

2.0

1.66

1.44

mmol/l

0.29

174

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

492

1.09

0.03

4.3

5.1

1.39

1.46

mmol/l

0.59

454

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

501

0.99

0.00

5.4

5.7

2.59

2.73

mmol/l

0.40

462

(36304419) Bacteria [Presence] in Urine

143

0.97

0.00

4.7

3.0

—

estimate

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

498

1.02

0.00

4.6

5.1

4.38

4.65

mmol/l

0.78

464

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

118

1.02

0.00

1.4

1.6

—

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

0.00

0.0

1.0

—

(3010813) Leukocytes [#/volume] in Blood

543

1.13

0.00

41.6

24.4

7.09

6.61

e9/l

0.94

533

(3026361) Erythrocytes [#/volume] in Blood

543

1.13

0.00

41.3

24.2

4.30

4.46

e12/l

1.19

532

(40759836) Histone Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

0.00

0.0

1.3

—

(3045142) Bone marrow Pathology biopsy report

0.00

0.0

1.2

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

0.0

1.3

—

13.93

—

(3029075) Extractable nuclear Ab panel - Serum

0.00

0.0

1.0

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

55.02

—

(40766800) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood

0.00

0.0

1.0

—

(40759850) Jo-1 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

0.0

1.3

—

(3021236) Streptolysin O Ab [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

91.67

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

-0.00

0.0

2.1

—

108.29

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

-0.00

0.0

1.8

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

-0.00

0.0

1.2

—

(3036071) Salmonella sp Ab [Titer] in Serum

0.00

-0.00

0.0

1.4

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.4

—

(3011648) Oxygen content in Venous blood

0.00

-0.00

0.0

3.9

—

11.10

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.4

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.4

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

-0.00

0.0

1.1

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.3

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

-0.00

0.0

1.4

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

-0.00

0.0

1.1

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

4.0

—

158.10

—

(44806420) Estimation of glomerular filtration rate

0.00

-0.00

0.0

1.4

—

(3007847) Interleukin 2 Receptor Soluble [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

1235.00

—

(3018333) Ribosomal P Ab [Presence] in Serum

0.00

-0.00

0.0

1.4

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

0.00

-0.00

0.0

1.6

—

674.57

—

(40768800) Prostate Pathology biopsy report

0.00

-0.00

0.0

1.2

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

0.00

-0.00

0.0

1.4

—

(4281824) Cell count and differential, peritoneal fluid

0.00

-0.00

0.0

1.0

—

(4146454) Self-monitoring of blood glucose

0.00

-0.00

0.0

3.2

—

(40758558) Short blood count panel - Blood

150

1.00

-0.00

8.9

8.1

—

(3007461) Platelets [#/volume] in Blood

542

1.15

-0.00

41.5

24.3

257.02

255.62

e9/l

0.05

536

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

-0.00

0.0

1.0

—

(3005570) Glucose [Moles/volume] in Urine

0.00

-0.00

0.0

2.4

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

1.8

—

(3015183) Erythrocyte sedimentation rate [Velocity] in Red Blood Cells

0.00

-0.00

0.0

1.0

—

15.20

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

-0.00

0.0

1.6

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

-0.00

0.0

1.2

—

(3028167) CD3+CD4+ (T4 helper) cells [#/volume] in Blood

0.00

-0.00

0.0

2.4

—

0.37

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

-0.00

0.0

2.1

—

1.20

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

1.02

-0.00

1.6

1.5

—

(21494434) Karyotype in Bone marrow

0.00

-0.00

0.0

1.0

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

-0.00

0.0

1.1

—

(4062490) Immunoglobulin typing, IgG

0.00

-0.00

0.0

1.4

—

(3042975) Streptococcus sp identified in Isolate by Organism specific culture

0.00

-0.00

0.0

1.0

—

(3006442) Creatine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.0

—

70.71

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

-0.00

0.0

2.1

—

4.03

—

Mortality – FinRegistry

↥

Association

Association between endpoint E4_THYMUSDISNAS and mortality.

Females

Parameter	HR [95% CI]	p-value
E4_THYMUSDISNAS	2.222 [1.27, 3.88]	0.005
Birth year	0.99 [0.98, 1.0]	0.02

During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 136 females with E4_THYMUSDISNAS died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have E4_THYMUSDISNAS.

N-year risk	Females	Males
1	0.203%	No data
5	1.219%	No data
10	2.736%	No data
15	5.372%	No data
20	9.043%	No data

Relationships between endpoints

↥

Index endpoint: E4_THYMUSDISNAS – Disease of thymus, other/unspecified

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Disease of thymus, other/unspecified

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints